UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026277
Receipt number R000030178
Scientific Title Clinical trial to investigate the efficacy and safety of fish skin-derived collagen on wall thickness in the carotid artery and clinical symptom, etc. in healthy adults and subjects with mild carotid artery hypertrophy by a double-blind parallel group comparison design
Date of disclosure of the study information 2017/02/25
Last modified on 2017/02/23 14:44:28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical trial to investigate the efficacy and safety of fish skin-derived collagen on wall thickness in the carotid artery and clinical symptom, etc. in healthy adults and subjects with mild carotid artery hypertrophy by a double-blind parallel group comparison design

Acronym

Clinical trial to investigate the efficacy and safety of fish skin-derived collagen on wall thickness in the carotid artery and clinical symptom, etc. in healthy adults and subjects with mild carotid artery hypertrophy by a double-blind parallel group comparison design

Scientific Title

Clinical trial to investigate the efficacy and safety of fish skin-derived collagen on wall thickness in the carotid artery and clinical symptom, etc. in healthy adults and subjects with mild carotid artery hypertrophy by a double-blind parallel group comparison design

Scientific Title:Acronym

Clinical trial to investigate the efficacy and safety of fish skin-derived collagen on wall thickness in the carotid artery and clinical symptom, etc. in healthy adults and subjects with mild carotid artery hypertrophy by a double-blind parallel group comparison design

Region

Japan


Condition

Condition

Healthy adults and subjects with mild carotid artery hypertrophy

Classification by specialty

Medicine in general Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the efficacy on IMT, Intima media-thickness, and safety of fish skin-derived collagen intake in healthy adults and subjects with mild carotid artery hypertrophy and to investigate the improvement of symptoms of chill of the whole body and constipation.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

To compare the rate of change in max-IMT from baseline after taking collagen for 12 weeks with collagen placebo group

Key secondary outcomes

To compare the amount of change in following items from baseline after taking collagen for 12 weeks with collagen placebo group
-max-IMT
-ABI : Ankle Brachial Index
-CAVI : Cardio-Ankle Vascular Index
-High-Sensitivity C-Reactive Protein
-Chill
-Constipation
-Velocity of blood flow and blood vessel thickness at capillary of the nail
-Blood pressure


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

YES

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

-Collagen group: Three packs of jelly containing 2.5g fish skin-derived collagen will be administered at least 30 minutes before breakfast with one 1000mg-tablet of Vitamin C.
-Duration time : 12 weeks

Interventions/Control_2

-Collagen placebo group: Three packs of placebo jelly will be administered at least 30 minutes before breakfast with one 1000mg-tablet of Vitamin C.
-Duration time : 12 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

-Subjects aged 40 years or older at the time of obtaining informed consent
-Healthy adults men and women
-Body mass index between 18.5 to 25 kg/m2
-max-IMT, Maximum Intima media-thickness, between 0.70 to 2.50mm
Then, it is classified into the following two groups by max-IMT.
Healthy adults : max-IMT, between 0.70 mm to 1.09mm 80 subjects
Subjects with mild carotid artery hypertrophy : max-IMT, between 1.10 mm to 2.50 mm 40 subjects

Key exclusion criteria

-Subjects who participated in any clinical trial within 4 months prior to administrating study foods.
-Subjects who had been taking supplements or Foods for Specified Health Uses mainly composed of collagen or placenta within 6 months prior to administrating study foods, and subjects who have ever taken Natural Marin Collagen Jelly (even once).
-Employees and family of implementation medical institution
-Pregnant or nursing women
-Subjects with low potential to comply with the study protocol and
subjects who are otherwise judged by the principal investigator or sub-investigator to be inappropriate for inclusion in the study

Target sample size

120


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hikaru Ishii

Organization

Kojinkai Medical Corporation Shin-Nihonbashi Ishii Clinic

Division name

Director

Zip code


Address

Shin-Edobashi Bldg, 8-6, Kobuna-cho, Nihonbashi, Chuo-ku Tokyo, 103-0024, Japan

TEL

03-3662-5901

Email

ishii@dr-wellness.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hikaru Ishii

Organization

Kojinkai Medical Corporation Shin-Nihonbashi Ishii Clinic

Division name

Director

Zip code


Address

Shin-Edobashi Bldg, 8-6, Kobuna-cho, Nihonbashi, Chuo-ku Tokyo, 103-0024, Japan

TEL

03-3662-5901

Homepage URL


Email

ishii@dr-wellness.co.jp


Sponsor or person

Institute

Kojinkai Medical Corporation Shin-Nihonbashi Ishii clinic

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 02 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2016 Year 12 Month 08 Day

Date of IRB


Anticipated trial start date

2017 Year 02 Month 27 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 02 Month 23 Day

Last modified on

2017 Year 02 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030178


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name